Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD | Market Cap | 321.21M |
| Revenue (ttm) | 5.59M |
| Net Income (ttm) | -13.25M |
| Shares Out | 600.40M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,833,070 |
| Average Volume | 1,939,109 |
| Open | 0.6150 |
| Previous Close | 0.6250 |
| Day's Range | 0.5250 - 0.6150 |
| 52-Week Range | 0.3050 - 0.7850 |
| Beta | 0.17 |
| RSI | 47.21 |
| Earnings Date | Feb 24, 2026 |
About Dimerix
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia. [Read more]
Financial Performance
In 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.
Financial StatementsNews
Dimerix Completes Enrolment In Phase 3 Trial Of DMX-200 In Focal Segmental Glomerulosclerosis
(RTTNews) - Dimerix Limited (DXB.AX) has completed adult patient enrolment in its pivotal ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis, successfully dosing its 286th patient...
Biotech Dimerix lands $940m licensing deal for kidney drug sales
The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.